{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=OTC-R", "query": { "intervention": "OTC-R" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T22:55:45.091Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05660681", "title": "Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dry Eye Disease" ], "interventions": [ { "name": "glycerin 0.7%/PEG 400 0.3%", "type": "DRUG" }, { "name": "polyethylene glycol 400 0.4%/propylene glycol 0.3%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calm Water Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2022-12-12", "completion_date": "2023-08-15", "has_results": false, "last_update_posted_date": "2023-09-06", "last_synced_at": "2026-09-06T22:55:45.091Z", "location_count": 1, "location_summary": "Andover, Massachusetts", "locations": [ { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660681" }, { "nct_id": "NCT02617407", "title": "Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dental Plaque" ], "interventions": [ { "name": "Livionex® Dental Gel", "type": "DRUG" }, { "name": "PreviDent 5000 plus/Tom's of Maine Children's toothpaste", "type": "DRUG" }, { "name": "Kolibree Toothbrush", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 44, "start_date": "2016-07-28", "completion_date": "2020-01-27", "has_results": false, "last_update_posted_date": "2024-09-23", "last_synced_at": "2026-09-06T22:55:45.091Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02617407" }, { "nct_id": "NCT06689865", "title": "Innovations in Hearing Accessibility and Technology (IHAT) Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hearing Loss", "Hearing Aids", "OTC Hearing Aids" ], "interventions": [ { "name": "HA-HCP", "type": "DEVICE" }, { "name": "OTC-HCP", "type": "DEVICE" }, { "name": "OTC-R", "type": "DEVICE" }, { "name": "OTC-SF", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 280, "start_date": "2024-11-13", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-09-06T22:55:45.091Z", "location_count": 2, "location_summary": "Aurora, Colorado • Boulder, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06689865" }, { "nct_id": "NCT00681265", "title": "Tear Film Break-up Time After Instillation of Artificial Tears", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Keratoconjunctivitis Sicca" ], "interventions": [ { "name": "glycerin", "type": "DRUG" }, { "name": "polyethylene glycol 400/propylene glycol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calm Water Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2008-06", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2012-10-26", "last_synced_at": "2026-09-06T22:55:45.091Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00681265" }, { "nct_id": "NCT02691507", "title": "Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "EpiCeram Skin Barrier Emulsion", "type": "DEVICE" }, { "name": "Experimental Product 1% Colloidal Oatmeal Balm", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Johnson & Johnson Consumer Inc. (J&JCI)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 53, "start_date": "2016-02", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2017-03-06", "last_synced_at": "2026-09-06T22:55:45.091Z", "location_count": 2, "location_summary": "Colorado Springs, Colorado • Richardson, Texas", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Richardson", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02691507" }, { "nct_id": "NCT00001337", "title": "Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma (DLBCL)", "Primary Mediastinal Large B-cell Lymphoma", "Burkitt Lymphoma", "Anaplastic Large-Cell Lymphoma", "Gray Zone Lymphoma" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "PET scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Laparotomy", "type": "PROCEDURE" }, { "name": "Ondansetron", "type": "OTHER" }, { "name": "Prochlorperazine", "type": "OTHER" }, { "name": "Omeprazole", "type": "OTHER" }, { "name": "Docusate Sodium + Sennosides", "type": "OTHER" }, { "name": "Lactulose", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DIAGNOSTIC_TEST", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 348, "start_date": "1993-05-08", "completion_date": "2024-05-24", "has_results": true, "last_update_posted_date": "2025-06-22", "last_synced_at": "2026-09-06T22:55:45.091Z", "location_count": 5, "location_summary": "Fort Lauderdale, Florida • Baltimore, Maryland • Bethesda, Maryland + 2 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001337" }, { "nct_id": "NCT03493841", "title": "Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis", "Progressive Multiple Sclerosis", "Secondary Progressive Multiple Sclerosis", "Primary Progressive Multiple Sclerosis" ], "interventions": [ { "name": "Alpha Lipoic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rebecca Spain", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-06-08", "completion_date": "2019-01-25", "has_results": false, "last_update_posted_date": "2019-03-22", "last_synced_at": "2026-09-06T22:55:45.091Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03493841" } ] }